SyncVision
Precision guidance system
SyncVision
Precision guidance system
The SyncVision precision guidance system is suitable with IntraSight and Core Integrated interventional platforms and streamlines lesion assessment, simplifies vessel sizing and enables precise therapy delivery all while integrating seamlessly in daily workflows in interventional suites of choice.
iFR Co-registration
IVUS Co-registration
iFR and IVUS Tri-Registration
Features
Angio+ vessel enhancement
The SyncVision Angio+ vessel enhancement tool provides clarity in visualizing vessels, which may include tortuous or overlapping vessels and highly stenosed lesions, potentially reducing the number of required views during diagnosis or therapy.
iFR Co-registration
With iFR Co-registration there is no need for hyperemic drugs, no need for time consuming pullback devices and no need for guesswork. Make length measurements without a cumbersome pullback device. Plan your procedure with physiologic guidance.
Quantitative coronary analysis
The SyncVision Angio+ quantitative coronary analysis automatically calculates lumen dimensions and stenosis in real time.
Specifications
- Power requirements
- System input
- 100V-120V, 50/60Hz, 220-240V, 50/60Hz, 600 VA
- Monitor
- 100-240V, 50/60Hz, 93 VA
- Workstation
- 100-240V, 50/60Hz, 250 VA
- Inputs
- Angiographic system video output
- Analog or digital
- IVUS system
- CORE system with IVUS version 3.4 and FFR 2.5.1 and IntraSight 5
- IVUS catheter
- Eagle Eye Platinum catheters
- Pressure Guidewire
- Verrata Plus
- Dimensions
- Workstation
- Height: 16.5", 39.6 cm; Width: 6.75", 16.2 cm; Depth: 21.25", 51 cm
- Bedside joystick
- Height: 1.5", 3.7 cm; Width: 4.2", 10.7 cm; Depth: 3", 7.6 cm
- Monitor
- Height: 15-19", 41-56 cm; Width: 15.8", 40.2 cm; Depth: 10", 24.7 cm
- Ordering Information
- SyncVision precision guidance system
- Sync002
Documentation
Related products
Disclaimer
1. Costa, Angiolillo DJ, Tannenbaum M, et al. Impact of Stent Deployment Procedural Factors on Long-term Effectiveness and Safety of Sirolimus-Eluting Stents (Final results of the Multicenter Prospective STLLR Trial). Am J Cardiol. 2008; 101(12):1704-1711.
2. Renata Rogacka, Azeem Latib, Antonio Colombo. IVUS-Guided Stent Implantation to Improve Outcome: A Promise Waiting to be Fulfilled. Curr Cardiol Rev. 2009;5(2):78–86.
3. Witzenbichler B, Maehara A, Weisz G, et al. Relationship Between Intravascular Ultrasound Guidance and Clinical Outcomes After Drug-Eluting Stents: The ADAPT-DES Study. Circulation. 2014;129:463-470.
4. 202-0013.53 SRS, Sync-Rx System pg 19,24.
5. Jakabcin J1, Spacek R, Bystron M, et al. Long-term health outcome and mortality evaluation after invasive coronary treatment using drug eluting stents with or without the IVUS guidance. Randomized control trial. HOME DES IVUS. Catheter Cardiovasc Interv. 2010;75(4):578-583.
6. 209-0030.02 Test Rpt, Use Validation, SyncVision. Pg. 9, Section 10.3; pg 14 – results.
7. 505-0100.18, Operator’s Manual. (pg 34).
8. 211-0013.31 Test Protocol, Philips Sync-Rx Wizard phase; 211-9913.07 Verification Protocol, Sync-Rx Co-Registration.
9. Patel, et al. ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 Appropriate use criteria for coronary revascularization focused update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol. 2012;59(9):857-881.
10. Kim SH, Kim YH, Kang SJ, et al. Long-term outcomes of intravascular ultrasound-guided stenting in coronary bifurcation lesions. Am J Cardiol. 2010;106(5):612-618.
11. Patel Y, Depta JP, Novak E, et al. Long-term outcomes with use of intravascular ultrasound for the treatment of coronary bifurcation lesions. Am J Cardiol. 2012;109(7):960-965.
12. Davies JE, et al. Coronary artery physiological stenosis mapping: application of pressure wire technology to measure stenosis significance, length, and predict the outcome of intervention. Abstract presented at PCR 2014
13. An iFR cut-point of 0.89 matches best with an FFR ischemic cut-point of 0.80 with a specificity of 87.8% and sensitivity of 73.0%. (iFR Operator’s Manual 505-0101.23)
14. Fractional Flow Reserve–Guided PCI versus Medical Therapy in Stable Coronary Disease. N Engl J Med. 2012;367(11):991-1001.
*Data on file
Product availability is subject to country regulatory clearance. Please contact your local sales representative to check the availability in your country.
Always read the label and follow the directions for use.
Philips medical devices should only be used by physicians and teams trained in interventional techniques, including training in the use of this device.
Philips reserves the right to change product specifications without prior notification.
©2025 Koniklijke Philips N.V. All rights reserved. Trademarks are the property of Koninklijke Philips N.V. or their respective owners.